Jak out of the box –targeting BTK, siglec-8, & Jak1 in food allergy

There has been rapid growth in the field of IgE-mediated food allergy therapeutics, with one FDA-approved therapy in 2020 and several others in various stages of investigation. Oral immunotherapy is the approach with the longest track record of study, and provides desensitization for most individuals undertaking therapy. However, therapy must be maintained for continued clinical protection, and side effects of therapy are frequent. There is a need to improve allergen immunotherapy safety and durability, and to provide a treatment that can target multiple food allergies.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Review Source Type: research